A phase I clinical trial (NCT03081910) investigating CD5-targeted CAR-T cells for T-cell malignancies is currently underway, marking an important step toward establishing the feasibility and safety of CAR-T immunotherapy in T-ALL [104]. This evidence concerns the gene CD5 and acute lymphoblastic leukemia.